Clinical Trials
147 trialsReduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Memorial Sloan Kettering Cancer Center
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
ACCESS
Center for International Blood and Marrow Transplant Research
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
OPTIMIZE
Center for International Blood and Marrow Transplant Research
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
St. Jude Children's Research Hospital
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
UNC Lineberger Comprehensive Cancer Center
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
Weill Medical College of Cornell University
Axi-cel in CNS Lymphoma
Dana-Farber Cancer Institute
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Cedars-Sinai Medical Center
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
City of Hope Medical Center
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Columbia University
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
City of Hope Medical Center
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation
West Virginia University
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Alliance for Clinical Trials in Oncology
BMT CTN 0903
Medical College of Wisconsin
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
St. Jude Children's Research Hospital
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
M.D. Anderson Cancer Center
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma
University of Wisconsin, Madison
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)
Medical College of Wisconsin
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
National Institutes of Health Clinical Center (CC)
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Roswell Park Cancer Institute
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
M.D. Anderson Cancer Center
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
M.D. Anderson Cancer Center
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Masonic Cancer Center, University of Minnesota
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
CTI BioPharma
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
M.D. Anderson Cancer Center
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Masonic Cancer Center, University of Minnesota
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Jonsson Comprehensive Cancer Center
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Case Comprehensive Cancer Center
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
St. Jude Children's Research Hospital
Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL
University of Texas Southwestern Medical Center
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
Roswell Park Cancer Institute
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
M.D. Anderson Cancer Center
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Alliance for Clinical Trials in Oncology
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
University of Pittsburgh
Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
University of Texas Southwestern Medical Center